Tolebrutinib

Last updated

Tolebrutinib
Tolebrutinib.svg
Clinical data
Trade names Cenrifki
Other namesPRN-2246; SAR-442168
Routes of
administration 		By mouth
Drug class Bruton's tyrosine kinase inhibitor
ATC code
Legal status
Legal status
Identifiers
  • 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]imidazo[4,5-c]pyridin-2-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C26H25N5O3
Molar mass 455.518 g·mol−1
3D model (JSmol)
  • C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5
  • InChI=1S/C26H25N5O3/c1-2-23(32)29-16-6-7-19(17-29)30-22-14-15-28-25(27)24(22)31(26(30)33)18-10-12-21(13-11-18)34-20-8-4-3-5-9-20/h2-5,8-15,19H,1,6-7,16-17H2,(H2,27,28)/t19-/m1/s1
  • Key:KOEUOFPEZFUWRF-LJQANCHMSA-N

Tolebrutinib, sold under the brand name Cenrifki, is a medication used for the treatment of multiple sclerosis. [1] It is a Bruton's tyrosine kinase inhibitor. [1] [3] It is taken by mouth. [1]

Contents

Tolebrutinib was authorized for medical use in the European Union in June 2026. [1] [2]

Medical uses

Tolebrutinib is indicated for the treatment of adults with secondary progressive multiple sclerosis without relapses in the last two years. [1]

Society and culture

In April 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cenrifki, intended for the treatment of multiple sclerosis. [1] The applicant for this medicinal product is Sanofi Winthrop Industrie. [1] Tolebrutinib was authorized for medical use in the European Union in June 2026. [1] [2]

Names

Tolebrutinib is the international nonproprietary name. [4]

Tolebrutinib is sold under the brand name Cenrifki. [5]

References

  1. 1 2 3 4 5 6 7 8 9 "Cenrifki EPAR". European Medicines Agency (EMA). 24 April 2026. Retrieved 28 May 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. 1 2 3 "Cenrifki PI". Union Register of medicinal products. 22 June 2026. Retrieved 12 July 2026.
  3. ↑ Turner TJ, Brun P, Gruber RC, Ofengeim D (June 2024). "Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis". Drugs in R&D. 24 (2): 263–274. doi:10.1007/s40268-024-00468-4. PMC   11315827 . PMID   38965189.
  4. ↑ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". WHO Drug Information. 34 (3). hdl: 10665/340680 .
  5. ↑ "Press Release: Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses" (Press release). Sanofi. 23 June 2026. Retrieved 12 July 2026.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.